RYTM
Rhythm Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.84B
P/E Ratio
—
EPS
$-3.11
Beta
2.14
52W High
$122.20
52W Low
$55.31
50-Day MA
$94.73
200-Day MA
$97.11
Dividend Yield
—
Profit Margin
-103.60%
Forward P/E
—
PEG Ratio
—
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $189.76M |
| Gross Profit (TTM) | $170.26M |
| EBITDA | $-190.68M |
| Operating Margin | -82.20% |
| Return on Equity | -90.40% |
| Return on Assets | -27.50% |
| Revenue/Share (TTM) | $2.92 |
| Book Value | $2.07 |
| Price-to-Book | 42.37 |
| Price-to-Sales (TTM) | 30.76 |
| EV/Revenue | 29.71 |
| EV/EBITDA | -12.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.90% |
| Shares Outstanding | $68.28M |
| Float | $55.45M |
| % Insiders | 0.81% |
| % Institutions | 108.94% |
Analyst Ratings
Consensus ($137.67 target)
4
Strong Buy11
Buy1
HoldData last updated: 4/9/2026